U.S. Markets closed

AzurRx BioPharma, Inc. (AZRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.8669+0.0081 (+0.94%)
At close: 4:00PM EDT
0.8669 0.00 (0.00%)
After hours: 07:56PM EDT

AzurRx BioPharma, Inc.

1615 South Congress Avenue
Suite 103
Delray Beach, FL 33445
United States
646 699 7855
http://www.azurrx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees12

Key Executives

NameTitlePayExercisedYear Born
Mr. James R. Sapirstein R.Ph., M.B.A.Pres, CEO & Chairman622kN/A1961
Mr. Daniel H. SchneidermanChief Financial Officer356.03kN/A1978
Dr. James E. PenningtonChief Medical Officer324.8kN/A1943
Mr. Martin Krusin M.B.A.Sr. VP of Corp. Devel.N/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency. It is also developing two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, including FW-420, for grade 1 Immune Checkpoint Inhibitor-associated colitis and diarrhea in oncology patients; and FW-1022, for COVID-19 gastrointestinal infections. AzurRx BioPharma, Inc. has a license agreement with First Wave Bio, Inc. The company was incorporated in 2014 and is headquartered in Delray Beach, Florida.

Corporate Governance

AzurRx BioPharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.